Efficacy of tiotropium and olodaterol combination therapy on dynamic lung hyperinflation evaluated by hyperventilation in COPD: an open-label, comparative before and after treatment study

References

• O’Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:770–777. doi:10.1164/ajrccm.164.5.201212211549531
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Laveneziana P. The clinical importance of dynamic lung hyperinflation in COPD. COPD. 2006;3:219–232.17361503
   PubMedGoogle Scholar
• O’Donnell DE, Webb KA, Neder JA. Lung hyperinflation in COPD: applying physiology to clinical practice. COPD Res Pract. 2015;1:1–12. doi:10.1186/s40749-015-0008-8
   Google Scholar
• Puente-Maestu L, Stringer WW. Hyperinflation and its management in COPD. Int J Chron Obstruct Pulmon Dis. 2006;1:381.18044095
   PubMedGoogle Scholar
• World Health Organization. Global Initiative for Chronic Obstructive Lung Disease, Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2019 report), 2019 [cited 226, 2019] Available from: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf.
   Google Scholar
• Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J. 2015;45:969–979. doi:10.1183/09031936.0013601425573406
   PubMed Web of Science ®Google Scholar
• Beeh KM, Westerman J, Kirsten AM, et al. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2015;32:53–59. doi:10.1016/j.pupt.2015.04.00225956072
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anzueto AR, Carter K, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir Med. 2018;6:337–344. doi:10.1016/S2213-2600(18)30102-429605624
   PubMed Web of Science ®Google Scholar
• O‘Donnell DE, Casaburi R, Frith P, et al. Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD. Eur Respir J. 2017;49:1601348. doi:10.1183/13993003.01348-201628424359
   PubMed Web of Science ®Google Scholar
• Gelb AF, Gutierrez CA, Weisman IM, Newsom R, Taylor CF, Zamel N. Simplified detection of dynamic hyperinflation. Chest. 2004;126:1855–1860. doi:10.1378/chest.126.6.185515596684
   PubMed Web of Science ®Google Scholar
• Kawachi S, Fujimoto K. Usefulness of a newly developed spirometer to measure dynamic lung hyperinflation following incremental hyperventilation in patients with chronic obstructive pulmonary disease. Intern Med. 2018. doi:10.2169/internalmedicine.1212-18
   Web of Science ®Google Scholar
• Fujimoto K, Kitaguchi Y, Kanda S, Urushihata K, Hanaoka M, Kubo K. Comparison of efficacy of long-acting bronchodilators in emphysema dominant and non-dominant COPD. Int J Chron Obstruct Pulmon Dis. 2011;6:219–227. doi:10.2147/COPD.S1846121660299
   PubMed Web of Science ®Google Scholar
• Fujimoto K, Yamazaki H, Ura M, Kitaguchi Y. Efficacy of tiotropium and indacaterol monotherapy and their combination on dynamic lung hyperventilation in COPD: a random open-label crossover study. Int J Chron Obstruct Pulmon Dis. 2017;12:3195–3201. doi:10.2147/COPD.S14905429138547
   PubMed Web of Science ®Google Scholar
• Mosley JF II, Smith LL, Dutton BN. Tiotropium bromide/olodaterol (Stiolto Respimat): once-daily combination therapy for the maintenance of COPD. P T. 2016;41:97.26908999
   PubMedGoogle Scholar
• Edsbäcker S, Johansson CJ. Airway selectivity: an update of pharmacokinetic factors affecting local and systemic disposition of inhaled steroids. Basic Clin Pharmacol Toxicol. 2006;98:523–536. doi:10.1111/j.1742-7843.2006.pto_355.x16700813
   PubMed Web of Science ®Google Scholar
• Sasaki E, Nakamura M, Kida K, et al. Reference values for spirogram and blood gas analysis in Japanese non-smoking healthy adults. J Jpn Respir Soc. 2001;39:383–399.
   Google Scholar
• Nishida S, Kambe M, Sewake N, Takano M, Kawane H. Pulmonary function in healthy subjects and its prediction-5: pulmonary diffusing capacity in adults. Jpn J Clin Pathol. 1976;24:941–947.
   PubMedGoogle Scholar
• Boren HG, Kory RC, Syner JC. The veterans administration army cooperative study of pulmonary function. Am J Med. 1966;41:96–114. doi:10.1016/0002-9343(66)90008-8
   Web of Science ®Google Scholar
• ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111–117. doi:10.1164/ajrccm.166.1.at110212091180
   PubMed Web of Science ®Google Scholar
• Roskell NS, Anzueto A, Hamilton A, Disse B, Becker K. Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol. Int J Chron Obstruct Pulmon Dis. 2014;9:813. doi:10.2147/COPD.S6017925114521
   PubMed Web of Science ®Google Scholar
• O‘Donnell DE, Flüge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23:832–840.15218994
   PubMed Web of Science ®Google Scholar
• Fujimoto K, Yoshiike F, Yasuo M, et al. Effects of bronchodilators on dynamic hyperinflation following hyperventilation in patients with COPD. Respirology. 2007;12:93–99. doi:10.1111/j.1440-1843.2006.00963.x17207032
   PubMed Web of Science ®Google Scholar
• Ichinose M, Minakata Y, Motegi T, et al. Efficacy of tiotropium/olodaterol on lung volume, exercise capacity, and physical activity. Int J Chron Obstruct Pulmon Dis. 2018;13:1407. doi:10.2147/COPD.S16602329750027
   PubMed Web of Science ®Google Scholar
• Singh D, Gaga M, Schmidt O, et al. Effects of tiotropium+ olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies. Respir Res. 2016;17:73. doi:10.1186/s12931-016-0387-727316465
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Decramer M, et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J. 2008;31:742–750. doi:10.1183/09031936.0012960718256071
   PubMed Web of Science ®Google Scholar
• Holland AE, Nici L. The return of the minimum clinically important difference for 6-minute-walk distance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187:335–336. doi:10.1164/rccm.201212-2191ED23418323
   PubMed Web of Science ®Google Scholar
• Casaburi R, Maltais F, Porszasz J, et al. Effects of tiotropium on hyperinflation and treadmill exercise tolerance in mild to moderate chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014;11:1351–1361. doi:10.1513/AnnalsATS.201404-174OC25289942
   PubMedGoogle Scholar
• Ferguson GT, Fležar M, Korn S, et al. Efficacy of tiotropium+ olodaterol in patients with chronic obstructive pulmonary disease by initial disease severity and treatment intensity: a post hoc analysis. Adv Ther. 2015;32:523–536. doi:10.1007/s12325-015-0218-026112656
   PubMed Web of Science ®Google Scholar
• Guideline for bioequivalence studies of generic products [homepage on the Internet]. Japan: Pharmaceutical and Food Safety Bureau; 2012 Available from: http://www.nihs.go.jp/drug/be-guidee/Generic/GL-E_120229_BE.pdf. Accessed 33, 2019.
   Google Scholar